<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332021000100014</article-id>
<article-id pub-id-type="doi">10.24875/rccar.m21000003</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Prevalence of lipid-lowering drug use]]></article-title>
<article-title xml:lang="es"><![CDATA[Prevalencia de uso de fármacos hipolipemiantes]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[Manuel E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gaviria-Mendoza]]></surname>
<given-names><![CDATA[Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[and Jorge E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Tecnológica de Pereira-Audifarma S.A Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Universitaria Autonóma de las Américas Grupo Biomedicina ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2021</year>
</pub-date>
<volume>28</volume>
<numero>1</numero>
<fpage>14</fpage>
<lpage>17</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332021000100014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332021000100014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332021000100014&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Among the main causes of death in Colombia, Latin America, and the general population are pathologies of cardiovascular origin, which have an important relationship with dyslipidemias.  Objective: The objective of the study was to establish the prevalence of the use of lipid-lowering drugs in a Colombian population during 2016.  Material and methods: A cross-sectional study was conducted using a population database of the Colombian Health System between January and June 2016. Site: outpatients of Colombia. Participants. Researchers considered all patients who had received this class of drug to establish the prevalence of the use of lipid-lowering drugs. Main measurements. Prevalence of use of lipid-lowering drugs.  Results: From a population of 4,328,688 patients, a total of 282,002 were prescribed a lipid-lowering drug; the mean age was 64.2 ± 13.3 years and women comprised 50.4% of the users. The estimated prevalence of lipid-lowering drug use was 6.5%. Statins (86.3%) were the most commonly used lipid-lowering drugs (atorvastatin: 81.0%, lovastatina: 14.4%) followed by fibrates (13.1%) and ezetimibe (0.6%).  Conclusions: A low proportion of people are being treated with lipid-lowering drugs, according to the estimated prevalence of dyslipidemia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Las patologías de origen cardiovascular son la primera causa de muerte en Colombia y América Latina, y la dislipidemia tiene una importante relación.  Objetivo: El objetivo fue establecer la prevalencia o proporción de uso de hipolipemiantes en una población colombiana durante el año 2016.  Materiales y métodos: Estudio de corte transversal a partir de una base de datos poblacional de pacientes afiliados al Sistema de Salud de Colombia entre enero y junio de 2016. Sitio. Pacientes ambulatorios de Colombia. Participantes. Se consideraron todos los pacientes que recibieron algún hipolipemiante, de cualquier sexo y mayores de 18 años. Mediciones principales: prevalencia de uso de hipolipemiantes.  Resultados: A partir de una población de 4328688 pacientes, se prescribieron hipolipemiantes a 282002, con una edad media de 64,2 13,3 años y el 50,4% eran mujeres. La prevalencia estimada de uso fue de 6,5%. Las estatinas (86,3%) fueron los hipolipemiantes más comúnmente utilizados (atorvastatina: 81,0%, locastatina: 14,4%) seguido de los fibratos (13,1%) y ezetimibe (0,6%).  Conclusiones: Una baja proporción de personas están siendo tratados con hipolipemiantes de acuerdo a la prevalencia estimada de dislipidemia para la población del país.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Statins]]></kwd>
<kwd lng="en"><![CDATA[Hypercholesterolemia]]></kwd>
<kwd lng="en"><![CDATA[Epidemiology]]></kwd>
<kwd lng="en"><![CDATA[Pharmacology]]></kwd>
<kwd lng="es"><![CDATA[Estatinas]]></kwd>
<kwd lng="es"><![CDATA[Hipercolesterolemia]]></kwd>
<kwd lng="es"><![CDATA[Epidemiología]]></kwd>
<kwd lng="es"><![CDATA[Farmacología]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lozano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Naghavi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Foreman]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shibuya]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Aboyans]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the global Burden of disease study 2010]]></article-title>
<source><![CDATA[Lancet (London, England)]]></source>
<year>2012</year>
<volume>380</volume>
<page-range>2095-128</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud y Protección Social-Colciencias-CINETS</collab>
<source><![CDATA[Guía de Práctica Clínica (GPC) Para la Prevención, Detección Temprana, Diagnóstico, Tratamiento y Seguimiento de las Dislipidemias en la Población Mayor de 18 Años, Guía No 27]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Bogotá, Colombia ]]></publisher-loc>
<publisher-name><![CDATA[ministerio de Salud y Protección Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caraballo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Grisales]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Flórez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Emilia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo para enfermedades cardiovasculares. Programa de prevención de la universidad de Antioquia]]></article-title>
<source><![CDATA[Rev Fac Nac Salud Pública]]></source>
<year>1997</year>
<volume>14</volume>
<page-range>90-108</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hobbs]]></surname>
<given-names><![CDATA[FD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular disease and lipids. Issues and evidence for the management of dyslipidaemia in primary care]]></article-title>
<source><![CDATA[Eur J Gen Pract]]></source>
<year>2003</year>
<volume>9</volume>
<page-range>16-24</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk factors prevalence among patients with dyslipidemia in Colombia]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Publica]]></source>
<year>2013</year>
<volume>30</volume>
<page-range>205-11</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mindell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aresu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zaninotto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Falaschetti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Poulter]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving lipid profiles and increasing use of lipid-lowering therapy in England:results from a national cross-sectional survey-2006]]></article-title>
<source><![CDATA[Clin Endocrinol]]></source>
<year>2011</year>
<volume>75</volume>
<page-range>621-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Primatesta]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Poulter]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lipid concentrations and the use of lipid lowering drugs:evidence from a national cross sectional survey]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2000</year>
<volume>321</volume>
<page-range>1322-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oesterle]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Laufs]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pleiotropic effects of statins on the cardiovascular system]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2017</year>
<volume>120</volume>
<page-range>229-43</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaviria-Mendoza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lipid-lowering drug prescriptions in a group of Colombian patients]]></article-title>
<source><![CDATA[Biomedica]]></source>
<year>2019</year>
<volume>39</volume>
<page-range>759-68</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Resolución Número 5592 de 2015, Por la Cual se Actualiza Integralmente el Plan de Beneficios en Salud Con Cargo a la Unidad de Pago por Capitación-UPC del Sistema General de Seguridad Social en Salud-SGSSS y se Dictan Otras Disposiciones. República de Colombia]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dalpino]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Sodré]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[de Faria]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of a hospital laboratory cohort to estimate the prevalence of dyslipidemia in an adult Brazilian population]]></article-title>
<source><![CDATA[Clin Chim Acta]]></source>
<year>2006</year>
<volume>367</volume>
<page-range>189-91</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Kwon]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and clinical characteristics of dyslipidemia in Koreans]]></article-title>
<source><![CDATA[Endocrinol Metab]]></source>
<year>2017</year>
<volume>32</volume>
<page-range>30-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joffres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tremblay]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Gorber]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dyslipidemia prevalence, treatment, control, and awareness in the Canadian health measures survey]]></article-title>
<source><![CDATA[Can J Public Health]]></source>
<year>2013</year>
<volume>104</volume>
<page-range>e252-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patino-Villada]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Arango-Velez]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
<name>
<surname><![CDATA[Quintero-Velasquez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Arenas-Sosa]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk factors in an urban Colombia population]]></article-title>
<source><![CDATA[Rev Salud Publica (Bogota)]]></source>
<year>2011</year>
<volume>13</volume>
<page-range>433-45</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tabatabaei-Malazy]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Qorbani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Samavat]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sharifi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Larijani]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fakhrzadeh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of dyslipidemia in Iran:A systematic review and meta-analysis study]]></article-title>
<source><![CDATA[Int J Prev Med]]></source>
<year>2014</year>
<volume>5</volume>
<page-range>373-93</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Puska]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Norrving]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Global Atlas on Cardiovascular Disease Prevention and Control:World Health Organization]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheidt-Nave]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Knopf]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Schienkiewitz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ziese]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nowossadeck]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of dyslipidemia among adults in Germany:results of the German health interview and examination survey for adults (DEGS 1)]]></article-title>
<source><![CDATA[Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz]]></source>
<year>2013</year>
<volume>56</volume>
<page-range>661-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mortensen]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary prevention with statins in the elderly]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2018</year>
<volume>71</volume>
<page-range>85-94</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Knowles]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Virani]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease]]></article-title>
<source><![CDATA[JAMA Cardiol]]></source>
<year>2017</year>
<volume>2</volume>
<page-range>47-54</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
